Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission - PubMed (original) (raw)
. 2005 Apr 1;105(7):2973-8.
doi: 10.1182/blood-2004-09-3660. Epub 2004 Dec 21.
Haesook T Kim, Katherine H Miller, Luxuan Guo, Emmanuel Zorn, Stephanie J Lee, Ephraim P Hochberg, Catherine J Wu, Edwin P Alyea, Corey Cutler, Vincent Ho, Robert J Soiffer, Joseph H Antin, Jerome Ritz
Affiliations
- PMID: 15613541
- PMCID: PMC1350982
- DOI: 10.1182/blood-2004-09-3660
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission
David B Miklos et al. Blood. 2005.
Abstract
Minor histocompatibility antigens (mHAs) are known targets of donor T cells after allogeneic hematopoietic stem cell transplantation (HSCT). In contrast, B-cell responses to mHAs have not been extensively characterized and the clinical significance of antibodies to mHAs is unknown. We tested 121 patients who underwent HSCT and 134 healthy donors for immunoglobulin G (IgG) antibodies against 5 mHAs encoded by genes on the Y chromosome (DBY, UTY, ZFY, RPS4Y, and EIF1AY). Antibodies to at least one H-Y protein developed in 52% of male patients with female donors compared with 8.7% of male patients with male donors (P < .0001), and in 41.4% of healthy females compared with 7.8% of healthy males (P < .0001). H-Y antibodies develop 4 to 12 months after transplantation and persist for long periods. The clinical significance of H-Y antibodies was characterized in 75 male patients with hematologic malignancies who received stem cells from female donors (F --> M HSCT). The presence of H-Y antibodies correlated with chronic graft-versus-host disease (GVHD) by univariate (odds ratio [OR] = 15.5; P < .0001) and multivariable logistic regression analysis (OR = 56.5; P < .0001). Antibody response to Y-chromosome encoded histocompatibility antigens (H-Y antigens) was also associated with maintenance of disease remission (P < .0001). B cells may provide a new target for immune intervention in chronic GVHD.
Figures
Figure 1.
Quantitation of IgG antibodies specific for H-Y and H-X proteins. This heatmap depicts IgG ELISA results for 39 sex-mismatched patients (A) and 29 healthy females (B) who developed antibody responses to any H-Y or H-X recombinant protein. Individual samples are represented in rows and each H-Y or H-X protein is represented in a separate column. Negative ELISA results are shown in light blue. The magnitude of positive ELISA results are represented by increasing tones of red. Below each H-Y antigen label, the mean ELISA result for the respective seropositive samples is presented.
Figure 2.
**Detection of DBY and UTY antibodies after stem cell transplantation.**Sixteen F → M HSCT patients had 5 or more serial plasma samples tested for DBY and UTY antibodies. All had one or more samples test H-Y antibody–negative before later samples tested positive, and 12 had at least 2 negative samples. Eleven patients developed both DBY and UTY antibodies. Four developed only DBY antibody, and one developed only UTY antibody. Smoothing spline curves are superimposed on the scatterplots for anti-DBY and anti-UTY.
Figure 3.
The cumulative incidence of chronic GVHD and relapse as a function of H-Y antibody response. Cumulative incidence of chronic GVHD (cGVHD) and disease relapse were determined as competing risks for H-Y antibody–positive and –negative patients. Those patients who did not experience chronic GVHD or relapse were censored at the time of last follow-up or death.
Similar articles
- Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors.
Miklos DB, Kim HT, Zorn E, Hochberg EP, Guo L, Mattes-Ritz A, Viatte S, Soiffer RJ, Antin JH, Ritz J. Miklos DB, et al. Blood. 2004 Jan 1;103(1):353-9. doi: 10.1182/blood-2003-03-0984. Epub 2003 Sep 25. Blood. 2004. PMID: 14512314 Free PMC article. - Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.
Spierings E, Kim YH, Hendriks M, Borst E, Sergeant R, Canossi A, Oudshoorn M, Loiseau P, Dolstra H, Markiewicz M, Leffell MS, Pereira N, Kircher B, Turpeinen H, Eliaou JF, Gervais T, Laurin D, Enczmann J, Martinetti M, Thomson J, Oguz F, Santarone S, Partanen J, Siekiera U, Alessandrino EP, Kalayoglu S, Brand R, Goulmy E. Spierings E, et al. Biol Blood Marrow Transplant. 2013 Aug;19(8):1244-53. doi: 10.1016/j.bbmt.2013.06.001. Epub 2013 Jun 10. Biol Blood Marrow Transplant. 2013. PMID: 23756210 - High-throughput allogeneic antibody detection using protein microarrays.
Paul J, Sahaf B, Perloff S, Schoenrock K, Wu F, Nakasone H, Coller J, Miklos D. Paul J, et al. J Immunol Methods. 2016 May;432:57-64. doi: 10.1016/j.jim.2016.02.009. Epub 2016 Feb 20. J Immunol Methods. 2016. PMID: 26902899 Free PMC article. - Clinical impact of H-Y alloimmunity.
Popli R, Sahaf B, Nakasone H, Lee JY, Miklos DB. Popli R, et al. Immunol Res. 2014 May;58(2-3):249-58. doi: 10.1007/s12026-014-8514-3. Immunol Res. 2014. PMID: 24781195 Free PMC article. Review. - Non-myeloablative transplants for malignant disease.
Storb RF, Champlin R, Riddell SR, Murata M, Bryant S, Warren EH. Storb RF, et al. Hematology Am Soc Hematol Educ Program. 2001:375-91. doi: 10.1182/asheducation-2001.1.375. Hematology Am Soc Hematol Educ Program. 2001. PMID: 11722994 Review.
Cited by
- HLA-mismatched allogeneic adoptive immune therapy in patients with severely immunosuppressed AIDS: a multicenter, open-label, controlled, phase 2a study.
Yang T, Xie Z, Xu Z, Tu B, Lu H, Huang H, Huang L, Zhang C, Gao L, Jin L, Ma P, Zou J, Liu L, Zhen C, Zhou C, Meng S, Li YY, Song JW, Yang S, Ai HS, Jiao Y, Shi M, Xu R, Wang FS. Yang T, et al. Emerg Microbes Infect. 2024 Dec;13(1):2364744. doi: 10.1080/22221751.2024.2364744. Epub 2024 Jun 27. Emerg Microbes Infect. 2024. PMID: 38935839 Free PMC article. Clinical Trial. - Donor/recipient Rh-mismatched allogeneic hematopoietic stem cell transplantation: transfusion strategy and allo-immunization to red blood cell antigens.
Xhaard A, Floch A, Ruggiu M, Robin M, Sicre de Fontbrune F, Michonneau D, Kaphan E, Prata PHL, Socié G, Traineau R, Peffault de Latour R, Leprêtre AC. Xhaard A, et al. Bone Marrow Transplant. 2024 Sep;59(9):1232-1238. doi: 10.1038/s41409-024-02316-0. Epub 2024 May 25. Bone Marrow Transplant. 2024. PMID: 38796632 - The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy.
Maurer K, Antin JH. Maurer K, et al. Front Immunol. 2024 Mar 15;15:1328858. doi: 10.3389/fimmu.2024.1328858. eCollection 2024. Front Immunol. 2024. PMID: 38558819 Free PMC article. Review. - Neoself Antigens Presented on MHC Class II Molecules in Autoimmune Diseases.
Jin H, Arase H. Jin H, et al. Adv Exp Med Biol. 2024;1444:51-65. doi: 10.1007/978-981-99-9781-7_4. Adv Exp Med Biol. 2024. PMID: 38467972 - Heightened TLR7 signaling primes BCR-activated B cells in chronic graft-versus-host disease for effector functions.
Bracken SJ, Suthers AN, DiCioccio RA, Su H, Anand S, Poe JC, Jia W, Visentin J, Basher F, Jordan CZ, McManigle WC, Li Z, Hakim FT, Pavletic SZ, Bhuiya NS, Ho VT, Horwitz ME, Chao NJ, Sarantopoulos S. Bracken SJ, et al. Blood Adv. 2024 Feb 13;8(3):667-680. doi: 10.1182/bloodadvances.2023010362. Blood Adv. 2024. PMID: 38113462 Free PMC article.
References
- Goulmy E, Schipper R, Pool J, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med. 1996;334:281–285. - PubMed
- Falkenburg JH, van de Corput L, Marijt EW, Willemze R. Minor histocompatibility antigens in human stem cell transplantation. Exp Hematol. 2003;31:743–751. - PubMed
- de Bueger M, Bakker A, Van Rood JJ, Van der Woude F, Goulmy E. Tissue distribution of human minor histocompatibility antigens: ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol. 1992;149:1788–1794. - PubMed
- Mutis T, Gillespie G, Schrama E, Falkenburg JH, Moss P, Goulmy E. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat Med. 1999;5:839–842. - PubMed
- Dickinson AM, Wang XN, Sviland L, et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med. 2002;8:410–414. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- HL70149/HL/NHLBI NIH HHS/United States
- P01 HL070149/HL/NHLBI NIH HHS/United States
- K08 HL069132/HL/NHLBI NIH HHS/United States
- U19 AI029530/AI/NIAID NIH HHS/United States
- AI29530/AI/NIAID NIH HHS/United States
- K08 HL69132/HL/NHLBI NIH HHS/United States
- P01 AI029530/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources